

**SUGGESTED FORMULA**

Progesterone 200mg PEG 1450 Troche

Version number: 1.0

Volume or quantity: 10 Troches

---

Progesterone, USP Micronized	2 g
Silica Gel (PPTD) Micronized	0.1 g
Stevioside	0.075g
Acesulfame Potassium FCC	0.05 g
Acacia, NF	0.165 g
Citric Acid USP Anhydrous Granular	0.115 g
Flavor, Tangerine Oil, Natural	0.1 mL
Flavor, Vanilla Extract (Pure)	0.04 mL
Flavor, Marshmallow, Artificial Concentrate	0.06 mL
Polyethylene Glycol 1450 MW, NF	7.79 g
Non-stick Cooking Spray	prn

---

**SUGGESTED COMPOUNDING PROCEDURES**

Calibrate Troche Mold and adjust formula as needed. This formula is based on approximately 1 g per troche. Flavors may be adjusted according to the patient's preference. Acesulfame Potassium works synergistically as a sweetener and can be added up to 0.5% or 5 mg per Troche. Do not increase Stevioside concentration beyond 7.5mg per Troche. Flavor oils may be added from 0.002 mL to 0.025mL per troche. Assume 80% displacement of PEG if powders are added or deleted.

Weigh all ingredients

1. Spray mold cavities with non-stick cooking spray and drain excess into paper towel.
2. Select appropriately sized beaker and melt PEG at 50° to 55°C and stir.
3. Triturate Progesterone, Silica Gel, Stevioside, Acesulfame Potassium, Acacia and Citric Acid in mortar to fine powder.
4. Sift the powders into the melted PEG and stir until uniform.
5. Add the flavors and mix.
6. Pour into troche mold
7. Allow to congeal.
8. Suggested Quality assessments:
  - a. color, texture, appearance
  - b. troche cavity filled / not overfilled
  - c. mixing and filling/potency studies

d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at Controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date estimated to be 180 days

**Precautions:**

Precautions should be taken when compounding hormones. These may be absorbed through skin, mucous membranes and lungs. Wear appropriate personal protective equipment – and inform personnel of the risk. Mix and prepare in vented enclosure (hood). Pregnant women and personnel with hormone related cancers should not compound hormone preparations.

05/15rd